NextCure (NXTC) EBITDA Margin (2019 - 2020)
NextCure (NXTC) posted EBITDA Margin of -168.97% for FY2020, up 379.04 percentage points from -548.01% in FY2019.
Powered by 
Analysis
NextCure (NXTC) EBITDA Margin (2019 - 2020) Analysis & Trends
- Business Quant data shows NXTC's EBITDA Margin at -548.01% in FY2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 39.16% |
| 10 | NextCure | 29.52 Mn | -91.24 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | 40.05% |
| Dec 31, 2019 | -560.75% |
| Sep 30, 2019 | -563.11% |
| Jun 30, 2019 | -597.22% |
| Mar 31, 2019 | -460.72% |
API Access
NextCure EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=NXTC&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "NXTC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=NXTC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();